Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-07-29

AUTHORS

Binod Dhakal, Anita D’Souza, Mehdi Hamadani, Carlos Arce-Lara, Katrina Schroeder, Saurabh Chhabra, Nirav N. Shah, Katelyn Gauger, Taylor Keaton, Marcelo Pasquini, Parameswaran Hari

ABSTRACT

In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m2), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3 + 3 dose escalation based on dose-limiting toxicities (DLTs) was employed in phase I (total 15); 2/6 patients developed DLTs (neutropenia and thrombocytopenia) at dose level 3 establishing the recommended phase II dose as bendamustine 80 mg/m2, ixazomib 4 mg, and dexamethasone 40 mg. The median age was 67 years (range, 42–72), and 43% were females. Patients received a median of 4 (range, 4–9) prior lines of therapy, of which ~50% were double refractory. In phase II, total 19 patients were treated. With a median follow-up of 17 months, 11% achieved very good partial response, 50% achieved partial response, and 27% achieved stable disease. Median progression free (PFS) and overall (OS) survival were 5.2 months (95% CI, 1.96–8.3) and 23.2 months (95% CI 16.3–30.07). The most frequent adverse events were anemia, thrombocytopenia, leukopenia, nausea, diarrhea, and infections. Peripheral neuropathy was infrequent. BID is a well-tolerated and effective combination therapy for patients with RRMM. More... »

PAGES

56

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41408-019-0219-3

DOI

http://dx.doi.org/10.1038/s41408-019-0219-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1119948742

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31358733


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bendamustine Hydrochloride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Boron Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dexamethasone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Safety", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dhakal", 
        "givenName": "Binod", 
        "id": "sg:person.01047372670.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047372670.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "D\u2019Souza", 
        "givenName": "Anita", 
        "id": "sg:person.01152771506.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152771506.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamadani", 
        "givenName": "Mehdi", 
        "id": "sg:person.01333152475.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333152475.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arce-Lara", 
        "givenName": "Carlos", 
        "id": "sg:person.0734612313.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734612313.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schroeder", 
        "givenName": "Katrina", 
        "id": "sg:person.010232444130.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010232444130.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chhabra", 
        "givenName": "Saurabh", 
        "id": "sg:person.012647475207.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012647475207.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shah", 
        "givenName": "Nirav N.", 
        "id": "sg:person.015270014615.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015270014615.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gauger", 
        "givenName": "Katelyn", 
        "id": "sg:person.011030024530.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011030024530.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Keaton", 
        "givenName": "Taylor", 
        "id": "sg:person.07371200517.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07371200517.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pasquini", 
        "givenName": "Marcelo", 
        "id": "sg:person.01355713277.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355713277.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hari", 
        "givenName": "Parameswaran", 
        "id": "sg:person.01170403141.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170403141.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/leu.2017.185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086000656", 
          "https://doi.org/10.1038/leu.2017.185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.335", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011949021", 
          "https://doi.org/10.1038/leu.2013.335"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026245496", 
          "https://doi.org/10.1038/leu.2013.313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41408-018-0104-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105908009", 
          "https://doi.org/10.1038/s41408-018-0104-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-07-29", 
    "datePublishedReg": "2019-07-29", 
    "description": "In this phase I/II trial, BID, bendamustine (70, 80, or 90\u2009mg/m2), ixazomib (4\u2009mg), and dexamethasone (40\u2009mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3\u2009+\u20093 dose escalation based on dose-limiting toxicities (DLTs) was employed in phase I (total 15); 2/6 patients developed DLTs (neutropenia and thrombocytopenia) at dose level 3 establishing the recommended phase II dose as bendamustine 80\u2009mg/m2, ixazomib 4\u2009mg, and dexamethasone 40\u2009mg. The median age was 67 years (range, 42\u201372), and 43% were females. Patients received a median of 4 (range, 4\u20139) prior lines of therapy, of which ~50% were double refractory. In phase II, total 19 patients were treated. With a median follow-up of 17 months, 11% achieved very good partial response, 50% achieved partial response, and 27% achieved stable disease. Median progression free (PFS) and overall (OS) survival were 5.2 months (95% CI, 1.96\u20138.3) and 23.2 months (95% CI 16.3\u201330.07). The most frequent adverse events were anemia, thrombocytopenia, leukopenia, nausea, diarrhea, and infections. Peripheral neuropathy was infrequent. BID is a well-tolerated and effective combination therapy for patients with RRMM.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41408-019-0219-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1045682", 
        "issn": [
          "2044-5385"
        ], 
        "name": "Blood Cancer Journal", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "refractory multiple myeloma", 
      "dose-limiting toxicity", 
      "phase I/II trial", 
      "II trial", 
      "partial response", 
      "multiple myeloma", 
      "dose level 3", 
      "phase II dose", 
      "good partial response", 
      "frequent adverse events", 
      "effective combination therapy", 
      "stable disease", 
      "median progression", 
      "prior lines", 
      "overall survival", 
      "adverse events", 
      "dose escalation", 
      "median age", 
      "peripheral neuropathy", 
      "combination therapy", 
      "double refractory", 
      "patients", 
      "phase I", 
      "months", 
      "bendamustine", 
      "phase II", 
      "ixazomib", 
      "myeloma", 
      "therapy", 
      "trials", 
      "level 3", 
      "leukopenia", 
      "nausea", 
      "lenalidomide", 
      "thrombocytopenia", 
      "neuropathy", 
      "diarrhea", 
      "anemia", 
      "infection", 
      "disease", 
      "dose", 
      "progression", 
      "response", 
      "median", 
      "survival", 
      "age", 
      "refractory", 
      "toxicity", 
      "females", 
      "escalation", 
      "years", 
      "events", 
      "m2", 
      "bid", 
      "lines"
    ], 
    "name": "Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma", 
    "pagination": "56", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1119948742"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41408-019-0219-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31358733"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41408-019-0219-3", 
      "https://app.dimensions.ai/details/publication/pub.1119948742"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_826.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41408-019-0219-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41408-019-0219-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41408-019-0219-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41408-019-0219-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41408-019-0219-3'


 

This table displays all metadata directly associated to this object as RDF triples.

265 TRIPLES      21 PREDICATES      100 URIs      88 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41408-019-0219-3 schema:about N1ea59671a0fa48c2b16864c438aeafcd
2 N317289e0614f4358a64a8e8be863e5c0
3 N3609739638ac47e8b93b7b7c8a86933a
4 N4efbd51fae8a4b05b590f1ff36b23d06
5 N61842ddd10074f829fb4941afb555fce
6 N7da6bf8258fb46b5acb653c17e9dcd4d
7 N814a0505884b40a38e765d7fce55e3c4
8 N84547cdd9c074b7bbfd6be10b267e5aa
9 N893874fb02a847c5beb26ac69cd9ad5b
10 Nadd4c2c61846481397951c856e5b52b6
11 Nb7d8a695514246ccadd64195a8ce3fee
12 Nc5025cebba0a4c6cba53319eb2801284
13 Nca16c1a6ca42426cb96416d187767e05
14 Nd3d0c302787f4f18a25655b18e0c4fb8
15 Ndff595a5ca9943f2986ba7e1c656a37c
16 Nfa077b6a088e4bb28f4fd775d59285f0
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N87738a0a19c041e39971b3b704d06d6b
20 schema:citation sg:pub.10.1038/leu.2013.313
21 sg:pub.10.1038/leu.2013.335
22 sg:pub.10.1038/leu.2017.185
23 sg:pub.10.1038/s41408-018-0104-5
24 schema:datePublished 2019-07-29
25 schema:datePublishedReg 2019-07-29
26 schema:description In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m2), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3 + 3 dose escalation based on dose-limiting toxicities (DLTs) was employed in phase I (total 15); 2/6 patients developed DLTs (neutropenia and thrombocytopenia) at dose level 3 establishing the recommended phase II dose as bendamustine 80 mg/m2, ixazomib 4 mg, and dexamethasone 40 mg. The median age was 67 years (range, 42–72), and 43% were females. Patients received a median of 4 (range, 4–9) prior lines of therapy, of which ~50% were double refractory. In phase II, total 19 patients were treated. With a median follow-up of 17 months, 11% achieved very good partial response, 50% achieved partial response, and 27% achieved stable disease. Median progression free (PFS) and overall (OS) survival were 5.2 months (95% CI, 1.96–8.3) and 23.2 months (95% CI 16.3–30.07). The most frequent adverse events were anemia, thrombocytopenia, leukopenia, nausea, diarrhea, and infections. Peripheral neuropathy was infrequent. BID is a well-tolerated and effective combination therapy for patients with RRMM.
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf Na876292e101e4695b69a1ad9cc3c5814
30 Nb56fa61a53054a4ca3256c9d1c095014
31 sg:journal.1045682
32 schema:keywords II trial
33 adverse events
34 age
35 anemia
36 bendamustine
37 bid
38 combination therapy
39 diarrhea
40 disease
41 dose
42 dose escalation
43 dose level 3
44 dose-limiting toxicity
45 double refractory
46 effective combination therapy
47 escalation
48 events
49 females
50 frequent adverse events
51 good partial response
52 infection
53 ixazomib
54 lenalidomide
55 leukopenia
56 level 3
57 lines
58 m2
59 median
60 median age
61 median progression
62 months
63 multiple myeloma
64 myeloma
65 nausea
66 neuropathy
67 overall survival
68 partial response
69 patients
70 peripheral neuropathy
71 phase I
72 phase I/II trial
73 phase II
74 phase II dose
75 prior lines
76 progression
77 refractory
78 refractory multiple myeloma
79 response
80 stable disease
81 survival
82 therapy
83 thrombocytopenia
84 toxicity
85 trials
86 years
87 schema:name Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
88 schema:pagination 56
89 schema:productId N57553e4bd03440489d8380b2910cf46d
90 N7957880b3a024ad6bc0949dc8d2c6c74
91 Ne1b4a2a2bda643c59f134206f4cea944
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1119948742
93 https://doi.org/10.1038/s41408-019-0219-3
94 schema:sdDatePublished 2022-09-02T16:03
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N4113db82c54e487599b038d527fefa69
97 schema:url https://doi.org/10.1038/s41408-019-0219-3
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N0b1c10849b7943eda29f4ecda8acca3f rdf:first sg:person.011030024530.33
102 rdf:rest N7ee79d44456b4eaebe8ba8c21cb836fa
103 N119c1f90131943879ea2723265456d8f rdf:first sg:person.01152771506.25
104 rdf:rest N3e5800471a6f447d83980071294be69d
105 N1ea59671a0fa48c2b16864c438aeafcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Dexamethasone
107 rdf:type schema:DefinedTerm
108 N29d42b8b74de4b71ab9a4c37b6c1e4d7 rdf:first sg:person.0734612313.59
109 rdf:rest Nddcc91c0bb6c45cebe981e857bd3419c
110 N317289e0614f4358a64a8e8be863e5c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Drug Resistance, Neoplasm
112 rdf:type schema:DefinedTerm
113 N3609739638ac47e8b93b7b7c8a86933a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Neoplasm Recurrence, Local
115 rdf:type schema:DefinedTerm
116 N3e5800471a6f447d83980071294be69d rdf:first sg:person.01333152475.54
117 rdf:rest N29d42b8b74de4b71ab9a4c37b6c1e4d7
118 N4113db82c54e487599b038d527fefa69 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 N4efbd51fae8a4b05b590f1ff36b23d06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Bendamustine Hydrochloride
122 rdf:type schema:DefinedTerm
123 N57553e4bd03440489d8380b2910cf46d schema:name dimensions_id
124 schema:value pub.1119948742
125 rdf:type schema:PropertyValue
126 N61842ddd10074f829fb4941afb555fce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Male
128 rdf:type schema:DefinedTerm
129 N7957880b3a024ad6bc0949dc8d2c6c74 schema:name pubmed_id
130 schema:value 31358733
131 rdf:type schema:PropertyValue
132 N7da6bf8258fb46b5acb653c17e9dcd4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Aged
134 rdf:type schema:DefinedTerm
135 N7ee79d44456b4eaebe8ba8c21cb836fa rdf:first sg:person.07371200517.29
136 rdf:rest N9a38f8b3b1334c11acc98aac4c719a20
137 N814a0505884b40a38e765d7fce55e3c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Multiple Myeloma
139 rdf:type schema:DefinedTerm
140 N84547cdd9c074b7bbfd6be10b267e5aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Boron Compounds
142 rdf:type schema:DefinedTerm
143 N87738a0a19c041e39971b3b704d06d6b rdf:first sg:person.01047372670.01
144 rdf:rest N119c1f90131943879ea2723265456d8f
145 N893874fb02a847c5beb26ac69cd9ad5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Adult
147 rdf:type schema:DefinedTerm
148 N9a38f8b3b1334c11acc98aac4c719a20 rdf:first sg:person.01355713277.54
149 rdf:rest Nf83625fca91a4947a707643600baf25d
150 N9b156ea40b684de49a6a5878205d1a4c rdf:first sg:person.015270014615.39
151 rdf:rest N0b1c10849b7943eda29f4ecda8acca3f
152 Na876292e101e4695b69a1ad9cc3c5814 schema:issueNumber 8
153 rdf:type schema:PublicationIssue
154 Nadd4c2c61846481397951c856e5b52b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Patient Safety
156 rdf:type schema:DefinedTerm
157 Nb56fa61a53054a4ca3256c9d1c095014 schema:volumeNumber 9
158 rdf:type schema:PublicationVolume
159 Nb7d8a695514246ccadd64195a8ce3fee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Antineoplastic Combined Chemotherapy Protocols
161 rdf:type schema:DefinedTerm
162 Nbaf98871e7b645169e95d9329127ff94 rdf:first sg:person.012647475207.14
163 rdf:rest N9b156ea40b684de49a6a5878205d1a4c
164 Nc5025cebba0a4c6cba53319eb2801284 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Female
166 rdf:type schema:DefinedTerm
167 Nca16c1a6ca42426cb96416d187767e05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Humans
169 rdf:type schema:DefinedTerm
170 Nd3d0c302787f4f18a25655b18e0c4fb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Glycine
172 rdf:type schema:DefinedTerm
173 Nddcc91c0bb6c45cebe981e857bd3419c rdf:first sg:person.010232444130.46
174 rdf:rest Nbaf98871e7b645169e95d9329127ff94
175 Ndff595a5ca9943f2986ba7e1c656a37c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Middle Aged
177 rdf:type schema:DefinedTerm
178 Ne1b4a2a2bda643c59f134206f4cea944 schema:name doi
179 schema:value 10.1038/s41408-019-0219-3
180 rdf:type schema:PropertyValue
181 Nf83625fca91a4947a707643600baf25d rdf:first sg:person.01170403141.13
182 rdf:rest rdf:nil
183 Nfa077b6a088e4bb28f4fd775d59285f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Treatment Outcome
185 rdf:type schema:DefinedTerm
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
190 schema:name Clinical Sciences
191 rdf:type schema:DefinedTerm
192 sg:journal.1045682 schema:issn 2044-5385
193 schema:name Blood Cancer Journal
194 schema:publisher Springer Nature
195 rdf:type schema:Periodical
196 sg:person.010232444130.46 schema:affiliation grid-institutes:grid.30760.32
197 schema:familyName Schroeder
198 schema:givenName Katrina
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010232444130.46
200 rdf:type schema:Person
201 sg:person.01047372670.01 schema:affiliation grid-institutes:grid.30760.32
202 schema:familyName Dhakal
203 schema:givenName Binod
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047372670.01
205 rdf:type schema:Person
206 sg:person.011030024530.33 schema:affiliation grid-institutes:grid.30760.32
207 schema:familyName Gauger
208 schema:givenName Katelyn
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011030024530.33
210 rdf:type schema:Person
211 sg:person.01152771506.25 schema:affiliation grid-institutes:grid.30760.32
212 schema:familyName D’Souza
213 schema:givenName Anita
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152771506.25
215 rdf:type schema:Person
216 sg:person.01170403141.13 schema:affiliation grid-institutes:grid.30760.32
217 schema:familyName Hari
218 schema:givenName Parameswaran
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170403141.13
220 rdf:type schema:Person
221 sg:person.012647475207.14 schema:affiliation grid-institutes:grid.30760.32
222 schema:familyName Chhabra
223 schema:givenName Saurabh
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012647475207.14
225 rdf:type schema:Person
226 sg:person.01333152475.54 schema:affiliation grid-institutes:grid.30760.32
227 schema:familyName Hamadani
228 schema:givenName Mehdi
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333152475.54
230 rdf:type schema:Person
231 sg:person.01355713277.54 schema:affiliation grid-institutes:grid.30760.32
232 schema:familyName Pasquini
233 schema:givenName Marcelo
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355713277.54
235 rdf:type schema:Person
236 sg:person.015270014615.39 schema:affiliation grid-institutes:grid.30760.32
237 schema:familyName Shah
238 schema:givenName Nirav N.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015270014615.39
240 rdf:type schema:Person
241 sg:person.0734612313.59 schema:affiliation grid-institutes:grid.30760.32
242 schema:familyName Arce-Lara
243 schema:givenName Carlos
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734612313.59
245 rdf:type schema:Person
246 sg:person.07371200517.29 schema:affiliation grid-institutes:grid.30760.32
247 schema:familyName Keaton
248 schema:givenName Taylor
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07371200517.29
250 rdf:type schema:Person
251 sg:pub.10.1038/leu.2013.313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026245496
252 https://doi.org/10.1038/leu.2013.313
253 rdf:type schema:CreativeWork
254 sg:pub.10.1038/leu.2013.335 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011949021
255 https://doi.org/10.1038/leu.2013.335
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/leu.2017.185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086000656
258 https://doi.org/10.1038/leu.2017.185
259 rdf:type schema:CreativeWork
260 sg:pub.10.1038/s41408-018-0104-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105908009
261 https://doi.org/10.1038/s41408-018-0104-5
262 rdf:type schema:CreativeWork
263 grid-institutes:grid.30760.32 schema:alternateName Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
264 schema:name Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
265 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...